Autism Spectrum Disorder Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021 - 2031
Summary
Autism spectrum disorder (ASD), also known as autism, is a highly heterogenous disorder characterized by varying social and communication impairments and pervasive repetitive behaviors, in addition to a wide range of associated non-core symptoms.
The ASD market is chronically underserved, with no approved treatments for the core symptoms or for most of the associated non-core symptoms. The only two treatments for ASD that are approved by the FDA are Johnson & Johnson’s Risperdal (risperidone) and Otsuka Pharmaceutical’s Abilify (aripiprazole). These atypical antipsychotics are both indicated for the treatment of irritability associated with ASD in children and adolescents. In Japan, only Abilify is approved for ASD, and there are no approved treatments in the 5EU. A wide variety of other drug classes are used off-label in the management of various symptoms associated with ASD.
Key Highlights
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook